Supernus Pharmaceuticals Net Change in Short-term Investments 2011-2024 | SUPN
Supernus Pharmaceuticals net change in short-term investments from 2011 to 2024. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
Supernus Pharmaceuticals Annual Net Change in Short-term Investments
(Millions of US $) |
| 2023 |
$269 |
| 2022 |
$-216 |
| 2021 |
$219 |
| 2020 |
$283 |
| 2019 |
$-157 |
| 2018 |
$-412 |
| 2017 |
$-73 |
| 2016 |
$-16 |
| 2015 |
$-26 |
| 2014 |
$0 |
| 2013 |
$-10 |
| 2012 |
$-48 |
| 2011 |
$9 |
| 2010 |
$26 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.512B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
